Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

Ponatinib (AP24534) is a novel multitargeted kinase inhibitor that potently inhibits native and mutant BCR-ABL at clinically achievable drug levels. Ponatinib also has in vitro inhibitory activity against a discrete set of kinases implicated in the pathogenesis of other hematologic malignancies, inc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Gozgit, Joseph M., Wong, Matthew J., Wardwell, Scott, Tyner, Jeffrey W., Loriaux, Marc M., Mohemmad, Qurish K., Narasimhan, Narayana I., Shakespeare, William C., Wang, Frank, Druker, Brian J., Clackson, Tim, Rivera, Victor M.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3236248/
https://ncbi.nlm.nih.gov/pubmed/21482694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-1044
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares